(Q46608065)

23 December 2017

title

Natural history of primary biliary cirrhosis. (English)

1 reference

23 December 2017

primary biliary cholangitis

main subject

0 references

author name string

Masanori Abe

series ordinal

1

1 reference

23 December 2017

Morikazu Onji

series ordinal

2

1 reference

23 December 2017

publication date

6 May 2008

1 reference

23 December 2017

published in

Hepatology Research

1 reference

23 December 2017

volume

38

1 reference

23 December 2017

issue

7

1 reference

23 December 2017

page(s)

639-645

1 reference

23 December 2017

Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis?

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2008.00351.X

Natural history of early primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2008.00351.X

Characterization of antimitochondrial antibodies in health adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2008.00351.X

Prevalence of antimitochondrial antibody in Japanese corporate workers in Kanagawa prefecture

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2008.00351.X

Familial primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2008.00351.X

Familial primary biliary cirrhosis in Hiroshima

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2008.00351.X

Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2008.00351.X

Significance of study on prevalence of AMA in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2008.00351.X

Asymptomatic primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2008.00351.X

The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2008.00351.X

Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2008.00351.X

Evaluation of fatigue in U.S. patients with primary biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2008.00351.X

Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2008.00351.X

Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2008.00351.X

Serum bilirubin: a prognostic factor in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2008.00351.X

Natural history of primary biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2008.00351.X

Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2008.00351.X

Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2008.00351.X

Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2008.00351.X

Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2008.00351.X

Prognosis in primary biliary cirrhosis: model for decision making

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2008.00351.X

Portal hypertension in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2008.00351.X

Esophagogastric varices as a prognostic factor for the determination of clinical stage in patients with primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2008.00351.X

Which patients with primary biliary cirrhosis or primary sclerosing cholangitis should undergo endoscopic screening for oesophageal varices detection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2008.00351.X

Prevalence and predictors of esophageal varices in patients with primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2008.00351.X

Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2008.00351.X

Hepatocellular carcinoma and survival in patients with primary biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2008.00351.X

A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2008.00351.X

The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2008.00351.X

Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2008.00351.X

The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2008.00351.X

Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2008.00351.X

The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2008.00351.X

Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2008.00351.X

Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2008.00351.X

Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2008.00351.X

Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2008.00351.X

Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2008.00351.X

10.1111/J.1872-034X.2008.00351.X

21 January 2018

Identifiers

DOI

1 reference

23 December 2017

1 reference

23 December 2017